This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Spain, Turkey, UK.
The drug LYNPARZA contains one active pharmaceutical ingredient (API):
1
|
UNII
WOH1JD9AR8 - OLAPARIB
|
|
Olaparib is a potent inhibitor of human poly (ADP-ribose) polymerase enzymes (PARP-1, PARP-2, and PARP-3), and has been shown to inhibit the growth of selected tumour cell lines in vitro and tumour growth in vivo either as a standalone treatment or in combination with established chemotherapies or new hormonal agents (NHA). |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| LYNPARZA Hard capsule | MPI, EU: SmPC | European Medicines Agency (EU) | |
| LYNPARZA Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| L01XK01 | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| AU | Pharmaceutical Benefits Scheme | 11050N, 11503K, 11522K, 11528R, 11539H, 12157W, 12161C, 12169L, 12170M |
| BR | Câmara de Regulação do Mercado de Medicamentos | 502317050031101, 502319020033801, 502319020033901 |
| CA | Health Products and Food Branch | 02454408, 02475200, 02475219 |
| EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | 2125-MEE-0516, 5534-MEE-1020, 5661-MEE-1120 |
| EE | Ravimiamet | 1673995, 1771196, 1771208, 1771219, 1771220, 1797925 |
| ES | Centro de información online de medicamentos de la AEMPS | 114959001, 114959002, 114959004 |
| FI | Lääkealan turvallisuus- ja kehittämiskeskus | 172731, 412504, 567228 |
| FR | Base de données publique des médicaments | 60058620, 64748533, 65789903 |
| GB | Medicines & Healthcare Products Regulatory Agency | 297475, 354988, 354991, 392406, 392408 |
| HK | Department of Health Drug Office | 64538, 65987, 65988 |
| IE | Health Products Regulatory Authority | 88871, 89038, 89039 |
| IL | מִשְׂרַד הַבְּרִיאוּת | 8453, 8454 |
| IT | Agenzia del Farmaco | 043794015, 043794027, 043794039, 043794041, 043794054 |
| JP | 医薬品医療機器総合機構 | 4291052F1027, 4291052F2023 |
| LT | Valstybinė vaistų kontrolės tarnyba | 1075368, 1085848, 1085849, 1085850, 1085851 |
| NL | Z-Index G-Standaard, PRK | 122947, 150959, 150967 |
| NZ | Medicines and Medical Devices Safety Authority | 18278, 19610, 19611 |
| PL | Rejestru Produktów Leczniczych | 100334749, 100405930, 100405946 |
| RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | W61522002, W64660001, W64661001 |
| SG | Health Sciences Authority | 15025P, 15662P, 15663P |
| TR | İlaç ve Tıbbi Cihaz Kurumu | 8699786092907, 8699786092914, 8699786092921, 8699786092938 |
| US | FDA, National Drug Code | 0310-0668, 0310-0679 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.